bioAffinity Technologies (BIAF) vs. Its Competitors Head to Head Analysis

bioAffinity Technologies (NASDAQ:BIAF) is one of 38 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare bioAffinity Technologies to related companies based on the strength of its risk, profitability, valuation, dividends, earnings, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings for bioAffinity Technologies and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	50	814	1297	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 10.14%. Given bioAffinity Technologies’ peers higher possible upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its peers.

Profitability

This table compares bioAffinity Technologies and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-249.68%	-18.55%	-11.34%

Volatility and Risk

bioAffinity Technologies has a beta of 3.93, meaning that its stock price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ peers have a beta of 6.26, meaning that their average stock price is 526% more volatile than the S&P 500.

Valuation & Earnings

This table compares bioAffinity Technologies and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-3.14
bioAffinity Technologies Competitors	$1.61 billion	$106.24 million	-0.43

bioAffinity Technologies’ peers have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 54.7% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by insiders. Comparatively, 15.6% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

bioAffinity Technologies peers beat bioAffinity Technologies on 9 of the 10 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.